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Abstract	
  
IMPROVING PROGNOSTIC MODELS IN BREAST CANCER WITH BIOSTATISTICAL
ANALYSIS OF THE PI3-KINASE PATHWAY.
Elliot James Rapp, Jena P. Giltnane, David L. Rimm, Annette Molinaro.
Department of Biostatistics, Yale School of Public Health, Yale University
School of Medicine, New Haven, CT.
Our hypothesis was that prognostic models for breast cancer that
incorporate both clinical variables and biomarkers in the PI3 Kinase molecular
pathway will improve upon the clinical models of TNM staging and the
Nottingham Prognostic Index (NPI). Our specific aim was to develop models
that misclassify fewer patients than TNM and NPI with the outcome of dead of
disease at ten years. Our population cohort was the YTMA49 cohort, a series of
688 samples of invasive ductal breast carcinoma collected between 1961 and
1983 by the Yale University Department of Pathology. Tissue MicroArray (TMA)
analysis was performed and biomarker expression level was determined using
Automated Quantitative Analysis (AQUA) technology for thirteen biomarkers in
the PI3 Kinase pathway, including an overall expression level and expression
levels by subcellular compartment. Eleven clinical variables were also
assembled from our cohort. Exhaustively searching the multivariate space, we
used logistic regression to predict our outcome of dead of disease at ten years.
Validation was performed using Leave One Out Cross Validation (LOOCV).
Misclassification estimates provided the means to compare different models,
with lower misclassification estimates indicating superior models. Confidence

intervals were constructed using bootstrapping with one thousand iterations.
We developed a helper computer program named Combination Magic to enable
us to develop sophisticated models that included both interactions between
variables and transformations of variables (e.g. logarithm).
Overall our best univariate models were NPI (misclassification estimate
(ME): 0.326, confidence interval (CI): 0.292 to 0.359), Nodal status (ME: 0.353,
CI: 0.322 to 0.493), and TNM (ME: 0.367, CI: 0.313 to 0.447). Our best
univariate models from the PI3 Kinase biomarkers were FOX01_NU (ME: 0.369,
CI: 0.336 to 0.415), AKT1_TM (ME: 0.373, CI: 0.335 to 0.412), and PI3Kp110_TM
(ME: 0.377, CI: 0.343 to 0.431). Our best bivariate models were
pTumor*PathER (ME: 0.328, CI: 0.308 to 0.443), pNode + NuGrade (ME: 0.333,
CI: 0.305 to 0.434), and AKT1_NN + Fox01_NU (ME: 0.338, CI: 0.307 to 0.391).
Our best trivariate models were pTumor + mTOR_NN + PI3Kp110_TM +
pTumor*PI3Kp110_TM (ME: 0.296, CI: 0.273 to 0.375), pTumor + AKT1_NU +
Fox01_NU + pTumor*AKT1_NU (ME: 0.298, CI: 0.275 to 0.38), and pTumor +
mTOR_TM + PI3Kp110_TM + pTumor*PI3Kp110_TM (ME: 0.299, CI: 0.276 to
0.378). Our best multi-variate model was Fox01_NU + AKT1_NU + mTOR_MB +
p70S6K_NU + AVG_BCL2_TM + Fox01_NU*AKT1_NU*mTOR_MB (ME: 0.295, CI:
0.274 to 0.393). None of these models was statistically superior to the clinical
models of TNM and NPI.
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Introduction	
  
Although many advances have been made in breast cancer treatment
over the last few decades, it remains a deadly disease with significant
financial, health, and emotional costs for breast cancer patients and survivors.
Of particular concern for both doctors and patients is likelihood of recurrence
after resection of the primary tumor. This likelihood can have an immediate
impact on choice of treatment, including the type of medical treatment and
the type of surgical resection, from lumpectomy to simple mastectomy to
radical mastectomy.
The likelihood of recurrence also carries an emotional toll long after
treatment of the primary tumor is completed. Many patients live in fear of
recurrence. Patients may choose a more aggressive chemotherapy treatment
than necessary, which carries its own health risks and litany of side effects.
Patients with a particularly high risk profile may even opt for prophylactic
mastectomy of a healthy breast.
Clinical models have been developed to assess the risk of metastasis in
breast cancer and are widely used in clinical practice, despite the fact that
their utility continues to be a matter of debate. The best known are TNM
staging and the Nottingham Prognostic Index (NPI). Each has been validated in
numerous clinical trials.
TNM staging is based on tumor size, number of positive lymph nodes, and
the presence of metastasis. The TNM classification of breast cancer was
updated in 2002 and again in 2009. As our work was performed prior to the
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2009 definition, the 2002 definition was used for this analysis. Although widely
used historically, TNM staging of breast cancer has been criticized as having
limited utility in actual clinical practice. As far back as 1992 Barr and Baum
called for its removal from clinical decision making, arguing that it ignores
many factors relevant to both surgical treatment and prognosis, and that
factors it does include are difficult to reliably assess clinically, with
unacceptably high false positive and negative rates (1).
More recently, Benson continues the criticism of the clinical utility of
TNM staging in breast cancer (2). He notes that TNM staging was developed at
a time when the pathological model of cancer metastasis was thought to
happen in an orderly, Halstedian fashion, with cancer spreading in a logical
manner from its site of origin to local lymph nodes to distant sites of
metastasis. However, small tumors with aggressive hematogenous spread do
not follow this model, and tend to be more aggressive than larger tumors with
lymphatic spread. Thus, TNM staging is particularly unhelpful for this type of
tumor, motivating the need for a more helpful alternative.
The NPI prognostic model is based on tumor size, number of positive
lymph nodes, and the histologic grade. It yields a continuous number that falls
into one of six prognostic groups, from Excellent Prognostic Group (EPG) to
Very poor Prognostic Group (VPG). NPI is the only breast cancer staging model
with prospective validation both intra and inter-center (3). It differs from TNM
in that it includes histologic grade, yet like TNM it does not incorporate
biomarkers. Thus, neither TNM staging nor the Nottingham Prognostic Index
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incorporate the growing body of knowledge regarding the significance of
different subtypes of breast cancer and the importance of metabolic and
signaling pathways in breast cancer growth and metastasis.
With advances in our understanding of the molecular pathways involved
in breast cancer, there has been renewed interest in developing prognostic
models that include biomarkers to overcome limitations of TNM staging and the
Nottingham Prognostic Index and more accurately predict metastasis and/or
recurrence in breast cancer. Significantly, laboratory tools such as Automated
Quantitative Analysis (HistoRX, New Haven, Connecticut) also allow us to more
accurately quantify expression levels of biomarkers in various pathways
significant in cancer, improving the accuracy and reproducibility of models
using biomarkers.
More accurate prognostic models will provide value to both physicians
and patients. Biomarker analysis can also provide important information about
the likely efficacy of various drugs that are targeted at different molecular
pathways active in breast cancer. A notable example is the use of the
pharmaceutical Trastuzumab to target the HER2/neu receptor, which has been
widely used in clinical practice since its FDA approval in 1998 (4).
After mutations of the p53 tumor suppressor gene, mutations within the
Phosphatidyl Inositol-3 Kinase (PI3 Kinase or PI3K) pathway are the most
common mutations leading to human cancer (5). Recent work has shown the
particular significance of PI3 Kinase mutations in human breast cancer (6).
Given the need for more accurate prognostic models in breast cancer, the
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likelihood that inclusion of biomarkers in prognostic models can improve upon
the existing clinical models, and the importance of the PI3K pathway in breast
cancer, we chose to evaluate whether a search of the covariate space of
various messengers in the PI3 Kinase pathway and clinical variables can offer
improved prognostic models when compared to the clinical gold standards of
TNM and NPI.

Specific	
  Aims	
  of	
  Thesis	
  
Aim	
  1	
  
Determine whether an exhaustive search of the covariate space of the
PI3 Kinase molecular pathway and clinical variables in metastatic breast cancer
can improve prognostic models over the existing clinical standards of TNM
staging and the Nottingham Prognostic Index (NPI) with the outcome of dead of
disease at ten years. Evaluate whether interactions between different
biomarkers in the PI3 Kinase pathway and logarithmic values can improve upon
the prognostic models previously identified.

Aim2	
  
Develop a reliable methodology to create and evaluate prognostic
models with an arbitrary number of interactions, sub-interactions, and custom
terms. In addition, structure our computational analysis to allow us to both
exhaustively search the model space and selectively create models by hand.
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Methods	
  
Statistical	
  Platform	
  
All computations were performed using The R Project for Statistical
Computing, an open-source statistical language and environment freely
available on the Internet (7).

Tumor	
  Cohort	
  
The YTMA49 cohort has been previously described (8). Briefly, it
consists of 688 samples of invasive ductal breast carcinoma collected between
1961 and 1983 from the Yale University Department of Pathology archives. The
mean and median age of diagnosis were 58.1 and 58.0, respectively. The mean
and median follow-up times were 12.8 and 8.9 years, respectively. The cohort
contains approximately half node-positive and half node-negative specimens.

Data	
  Acquisition	
  
Data acquisition was performed by Jena Giltnane, at the time a MD/PhD
candidate at Yale University School of Medicine. She analyzed 539 metastatic
breast cancer biopsy cores from the YTMA49 cohort using Automated
Quantitative Analysis (described below). In addition to quantifying expression
levels of thirteen biomarkers in the PI3 Kinase pathway (see Table One), she
assembled eleven clinical variables (see Table Two). Together, these 24
variables were included as the covariates for model building. However, as
noted below, each biomarker was further characterized by its expression level
in three subcellular compartments. Thus, there were a total of 63 possible
inputs to our model generation (52 biomarkers and 11 clinical variables).
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AQUA	
  Analysis	
  of	
  the	
  PI3	
  Kinase	
  Pathway	
  
Automated Quantitative Analysis (HistoRX, New Haven, Connecticut),
known as AQUA, has been previously described (9). Traditional scoring of
protein expression performed by pathologists using immunohistochemistry and
visual inspection of tumor slides is limited by inter-operator variability and lack
of reproducibility. AQUA technology assigns a value from 0 to 255 to represent
the level of biomarker expression, with a higher number indicating greater
expression. Its increased granularity of expression levels and high
reproducibility when compared to traditional methods is designed to allow for
more accurate prognostic models.
When performing AQUA quantification, the technician distinguishes areas
of tumor from stromal elements by staining with antikeratin and creating an
epithelial tumor mask. After the operator visual sets an intensity threshold to
distinguish between cancerous and non-cancerous areas, the AQUA software
defines each area as “on” (tumor) or “off” (non-tumor). By convention, TM
(“Tumor Mask”) describes the overall expression level in cancerous cells.
In addition, AQUA allows quantification of protein expression by
subcellular compartmentalization. NU (“Nuclear”) describes the expression
level in the nuclear compartment. MB (“Membrane”) describes the expression
level in the cellular membrane. NN (“Non-Nuclear”) describes the expression
level in the non-nuclear, non-membranous portion of the cell. The ability to
localize biomarkers in the PI3 Kinase pathway by subcellular compartment is
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designed to allow for improved prognostic models by more precisely describing
the metabolic activity of the pathway.

Model	
  Search	
  
One of the challenges of our analysis was model selection. One
possibility is to use artificial intelligence algorithms to search the model space
and use pruning techniques to eliminate unfavorable portions of the covariate
space. This is potentially advantageous given limited computing resources.
However, without deep understanding of the domain space, it is difficult to
accurately predict which portions of the covariate space are unfavorable for
analysis. Another possibility is to use classic Classification and Regression
Trees (CART) (10) to determine good variables on which to split and then
construct models by hand. Although this lessens the dependence of model
quality on the researcher’s domain expertise, it remains prone to error. The
most foolproof method, given sufficient computing resources, is to exhaustively
search the variable space. With the availability of two high-performance
clusters (described below) on which to perform our analysis, we chose the
exhaustive search option.
With exhaustive search of the covariate space, it becomes imperative to
accurately create all possible combinations of variables for models of varying
complexity (e.g., univariate, bivariate, trivariate, and so forth). Given
combinatorial explosion, this can be a time-consuming task. In addition, we
desired the ability to create specialized runs with models that included
straightforward interactions of the form “Y ~ A*B*C”, where Y is the outcome
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and A, B, and C are inputs, sub-interactions of the form “Y ~ A + B+ C + A*B”,
where “A*B” defines an interaction between A and B in addition to their
independent effects, and custom and/or transformed terms (e.g., logarithmic
terms, such as Y ~ A + log(B/C)).

Logistic	
  Regression	
  Analysis	
  and	
  Misclassification	
  
Given that our goal was to improve prognostic models of breast cancer,
we chose dead or alive of disease as our outcome. An important consideration
was the appropriate time interval. Shorter time intervals would classify
patients with later recurrence as having “survived” breast cancer. Longer time
intervals would compromise the analysis by introducing the confounding nature
of comorbidities that are common in older patients, as well as increasing the
number of patients that did not have sufficient follow up. A ten year time
interval was chosen as a compromise. Thus, our outcome was death due to
breast cancer within ten years of the initial diagnosis.
As we needed a statistical methodology that would predict this binary
outcome, we chose logistic regression. The logistic regression computation was
performed using R’s glm (“generalized linear model”) function.

Leave	
  One	
  Out	
  Cross	
  Validation	
  
In order to estimate prediction error of our models, we chose Leave One
Out Cross Validation (LOOCV). In this methodology, each patient is left out of
the training set in turn and used in the test set. A logistic regression analysis is
performed on the training set. Maintaining the parameters of the resulting
model, if it correctly predicts the outcome (i.e., alive or dead at ten years) for
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the patient left out (i.e., the single patient in the test set), then its
classification is correct. If it incorrectly predicts this outcome, then its
classification is incorrect. After all n-iterations of LOOCV, there are as many
classifications as patients. By dividing the incorrect classifications by the total
number of classifications, we arrive at a misclassification estimate. Our goal in
this research project was to minimize the misclassification estimate, thereby
improving our ability to accurately predict alive/dead status at ten years.
Note that due to missing data values, not every patient will be included
in the analysis when creating a misclassification estimate for a given model.
Thus, as a measure of quality, we counted the number of successful predictions
that were used to construct each misclassification estimate (the denominator
of the misclassification estimate).
In addition to misclassification, we computed Area Under the Curve
(AUC) from ROC curves (Receiver Operator Curves). The ROC curves were
constructed using R’s rcorr.cens function from the Hmisc library (11).
In order to format the data in a manner palatable to R, we were
required to make a number of changes. For example, R does not allow
numerals at the start of column or row names in a data table. Another
potential issue was “factor” variables. These include classification variables
(e.g., TumorType could be Ductal or Lobular) and ordinal variables
(pathologist-scored biomarker expression level scored as a 0, 1, 2 or 3). In R,
the former group is automatically recognized, whereas the latter group must
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be explicitly designated as a factor; otherwise, it will be interpreted as a
continuous variable.
Another consideration was the alphabetical order of the factor names.
This is due to the fact that R designates whichever factor is first alphabetically
as the baseline. In order to set the factor with the largest number of instances
as baseline, we would programmatically recode the values when necessary,
using 0, 1, 2 … n to represent the various categories in order of prevalence,
and then explicitly designate each relevant variable as a factor to prevent its
interpretation as a continuous variable.

Bootstrapping	
  and	
  Confidence	
  Intervals	
  
Next, we needed to develop confidence intervals for our models,
allowing us to compare two models and determine whether their
misclassification estimates were statistically different. A common method for
forming confidence intervals is via bootstrapping, which entails building
training sets by sampling the data with replacement (12). This did not change
the total number of patients in the training set, but it did mean that patients
could be included two or more times, whereas other patients would not be
included at all. By repeating this process 1000 times, it was possible to
construct a confidence interval by evaluating the 2.5 and 97.5 percentiles.

Cluster	
  Runs	
  
Runs were performed on two different high-performance computing
clusters maintained by the Yale University Life Sciences Computing Center,
supported by NIH Grant RR19895. The first, BulldogC, contains one hundred
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and thirty compute nodes. Each consists of dual 3.2 Ghz EM64T Xeon, 64-bit
processors with eight GB of available RAM. The second, BulldogI, contains one
hundred and seventy compute nodes. Each consists of two dual core 3.0 GHz
Xeon 5160 processors with sixteen GB of available RAM. Runs varied greatly in
complexity and required anywhere from a few hours to a week of processing
time spread over one to one hundred and eighty processors.
Given the enormous size and complexity of the runs, gracefully
recovering from errors and having the ability to re-run selective inputs became
a priority. As noted earlier, we gained the ability to reproduce parts of the run
by extracting model creation from the analysis code and passing discrete units
of work into the R analysis function (represented by our input files).
R was particularly sensitive to some data configurations. This was
especially true in the case of factor variables. For example, in cases of a
patient with a unique value for a factor variable, a R run-time error would
occur when the patient was left out of model creation and then used for
prediction during LOOCV. Such a failure would cause the entire input file to
fail and it was difficult to pinpoint the responsible formula. To gracefully
recover from these errors, we wrapped with R’s tryCatch function the code for
generating the logistic regression model, making the prediction, and computing
the Area Under the Curve (AUC).

17

Results	
  
Univariate	
  Results	
  
Univariate

Mis.Est.

AUC

n

Mean

0.025

0.975

NPI

0.326

0.644

473

0.326

0.292

0.359

~pNodal Stage

0.353

0.597

539

0.372

0.322

0.493

TNM

0.367

0.609

0.367

0.313

0.447

~Metastasis
Stage

0.368

0.537

536

0.367

0.334

0.398

~Fox01_NU

0.369

0.524

434

0.375

0.336

0.415

~AKT1_TM

0.373

0.5

415

0.374

0.335

0.412

~PI3Kp110_TM

0.377

0.539

403

0.386

0.343

0.431

~mTOR_TM

0.382

0.5

429

0.383

0.346

0.419

~NFkB_TM

0.383

0.5

439

0.389

0.35

0.433

~HER2_MB

0.385

0.524

535

0.391

0.357

0.425

Figure	
  1:	
  Selected	
  Univariate	
  Results	
  
Not surprisingly, the clinical models of NPI and TNM were superior to any
single biomarker in the PI3 Kinase pathway. This is likely because each of
these clinical models incorporates multiple data points into a single marker of
disease severity. Interestingly, nodal status (the presence of metastasis in
adjacent lymph nodes) was by itself slightly (but not significantly) more
predictive than TNM overall, followed closely by whether or not the disease
had metastasized distantly. Of the PI3 Kinase variables, the nuclear
localization of Fox01 and the overall expression of AKT1 were most predictive.
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Bivariate	
  Results	
  
Bivariate

Mis.Est.

AUC

n

Mean

0.025

0.975

pTumor * PathER

0.328

0.632

472

0.357

0.308

0.443

pNode + NuGrade

0.333

0.645

502

0.357

0.305

0.434

AKT1_NN +
Fox01_NU

0.338

0.54

349

0.349

0.307

0.391

Figure	
  2:	
  Selected	
  Bivariate	
  Results	
  
Although our top three bivariate models all approached the univariate
NPI model with misclassifications of 0.328, 0.333, and 0.338, respectively,
none of them were quite able to match its 0.326 misclassification estimate.
Furthermore, whereas the 95% confidence interval for misclassification by NPI
was only 0.067 wide, the confidence intervals for two of our two top three
bivariate models were considerably wider, indicating a greater likelihood that
in future analysis our favorable results would not be replicated on independent
data sets

Trivariate	
  Results	
  
Trivariate
Mis.Est.

AUC

n

Mean

0.025

0.975

pTumor +
mTOR_NN +
PI3Kp110_TM +
pTumor*PI3Kp110
_TM

0.296

0.648

311

0.322

0.273

0.375

pTumor +
AKT1_NU +
Fox01_NU +
pTumor*AKT1_N
U

0.298

0.620

332

0.323

0.275

0.38
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pTumor +
mTOR_TM +
PI3Kp110_TM +
pTumor*PI3Kp110
_TM

0.299

0.648

311

0.326

0.276

0.378

Figure	
  3:	
  Selected	
  Trivariate	
  Results	
  
With the additional information provided by a third variable, our top
three trivariate results showed considerable improvement over our best
bivariate results. They each had an improved misclassification estimate over
NPI. However, they also had a relatively wide 95% confidence interval of
approximately 0.1. Thus, the 95% confidence intervals of each overlapped with
the 95% confidence intervals of the clinical models of TNM and NPI, and as a
result none of the results were statistically significant.

Multi-‐Variate	
  Results	
  
Mis.
Est.

AUC

n

Mean

0.025

0.975

Fox01_NU + AKT1_NU +
mTOR_MB + p70S6K_NU
+ AVG_BCL2_TM +
Fox01_NU*AKT1_NU*mT
OR_MB

0.295

0.587

285

0.33

0.274

0.393

Fox01_NU + AKT1_NU +
mTOR_MB +
AVG_BCL2_TM +
p70S6K_NN +
Fox01_NU*mTOR_MB*p7
0S6K_NN

0.302

0.574

285

0.33

0.277

0.391

Fox01_NU + AKT1_NU +
mTOR_MB + AKT2_NN +
AVG_BCL2_TM +
p70S6K_NN +
Fox01_NU*AKT1_NU*mT
OR_MB

0.295

0.593

285

0.331

0.273

0.401

Fox01_NU + AKT1_NU +
mTOR_MB + cmyc_NU +

0.297

0.627

195

0.333

0.266

0.403

20

AVG_BCL2_TM +
p70S6K_NN +
AKT1_NU*p70S6K_NN

Figure	
  4:	
  Selected	
  Multivariate	
  Results	
  
Our top multivariate (i.e., greater than trivariate) results did not show
improvement over our best trivariate models. Misclassification estimates were
similar but the confidence intervals widened.

Discussion	
  
Significance	
  of	
  Study	
  Results	
  
Our results were not significant when compared to the commonly used
clinical models of TNM and NPI. There are several possible reasons for this,
including issues with missing data values, incomplete patient follow up in the
YTMA49 cohort, choice of statistical methodology, and the significance of other
biological pathways besides the PI3 Kinase pathway in breast cancer.
First, there was a moderate amount of missing data, including clinical
variables that were not available and AQUA variables that could not be
computed due to inadequate tumor cores. Logistic regression drops patients
that do not have all values for all variables in the model, which leads to
reduced accuracy of the model.
Furthermore, patients with missing data values were also not available
when creating our confidence intervals with bootstrapping. With a smaller
number of patients, this may have caused our confidence intervals to be wider
than they would have been otherwise, and could have sacrificed statistical

21
significance in some cases. Although it carries its own risks, imputing data may
have improved our model accuracy and reduced our confidence intervals by
making these patients available for regression analysis.
Second, there was incomplete and inconsistent follow up of patients in
the YTMA49 cohort. This may have led to patients that were incorrectly
classified as dead of disease that in actuality died of another cause. It may
also have led to patients that were incorrectly classified as dying of another
cause. In addition, some patients were lost to follow up altogether.
Third, our results may also have suffered from our choice of outcome.
The use of dead-of-disease at ten years arbitrarily separates a patient who has
recurrence leading to death at nine years from one having the same outcome
at ten years, even though these patients are effectively the same from a
survival perspective. Instead, choosing random forests with survival trees may
have improved our results by eliminating the arbitrary cutoff of ten years (13,
14). Another option would be to use dead of disease at 15 years instead of 10
years, given that the longer timeframe should eliminate the majority of late
recurrences. Separately, removing patients older than 80 would eliminate the
confounding nature of the significant comorbidities in this elderly group of
patients.
Perhaps most significantly, since our study was designed, the importance
of other pathways in breast cancer besides the PI3 Kinase pathway has become
increasingly apparent. This includes the p53 pathway and several others as
well (15). In some cases, multiple pathways may operate independently. In
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other cases, the pathways may have a dependency on each other. For this
reason, despite the tradeoff of a smaller cohort of patients, our analysis may
have benefited from a focus only on the HER2-positive cases, as these are the
cases for which the activity of the PI3-Kinase pathway has the most
importance.
Obviously, future studies of the potential of biomarker analysis to
improve breast cancer prognosis would likely also benefit from the inclusion of
other biological pathways that are significant in breast cancer.

Statistical	
  Methodology	
  
Commonly, two statistical methodologies are used to create prognostic
models to predict a binary outcome in human disease. These are logistic
regression and artificial neural network models (16). Other methodologies
include k-Nearest Neighbors, Linear Discriminant Analysis, and Classification
and Regression Trees (10).
Significant advantages of logistic regression are that the methodology is
well established and the coefficients of the models have intuitive clinical
interpretations (17). This allows us to compare the relative importance of
various actors within the dysregulated PI3 Kinase pathway in breast cancer.
Furthermore, logistic regression has been used in previous studies attempting
to evaluate clinical models for breast cancer diagnosis (18, 19), and we were
interested in comparing molecular models developed by this methodology to
the clinical models used in practice.
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Artificial neural networks are another viable option. They have the
advantage of not assuming a linear relationship between the model inputs and
its outcome. However, they are prone to over-fitting. Additionally, their
“black box” nature makes it impossible to reliably compare the relative
importance of the various inputs in the model (17). For the above reasons, we
chose to use logistic regression over artificial neural networks in our analysis.
However, in practice artificial neural networks have often performed
well in elucidating previously unforeseen predictors in prognostic studies. It
would be instructive in a future study to compare the performance of artificial
neural networks to the performance of logistic regression with regard to
predicting survival in the YTMA49 cohort.

Cross	
  Validation	
  
There are many methods of performing cross validation. The three most
commonly used are v-fold Cross Validation, Leave One Out Cross Validation,
and Monte Carlo Cross Validation.
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Figure	
  5:	
  v-‐fold	
  Cross	
  Validation	
  
In v-fold Cross Validation, the cohort is split into v equal partitions. v-1
of these partitions are used for the training set, while the vth partition is used
for the test set. In the next iteration, a different partition is used for the test
set, while the remaining partitions are again used for the training set, and the
process repeats. Thus, each partition is used as the test set exactly once and
is included in the training set v-1 times.
Leave One Out Cross Validation (LOOCV) is the most extreme example of
v-fold cross validation, where n is the size of the sample and v = n. This means
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that the regression analysis is performed n times, the size of the training set is
n-1 patients, the size of the test set is one patient, and each patient is in the
test set exactly once. Its thoroughness results in a smaller bias than lesser
forms of v-fold cross validation. A tradeoff is that it is the most
computationally intensive form of v-old cross validation.

Figure	
  6:	
  Leave	
  One	
  Out	
  Cross	
  Validation	
  
However, the fact that it is the most computationally intensive does not
necessarily make it superior to cross validation with smaller values for v. This
is due to the fact that the n test sets are very similar to each other, resulting
in a high variance. The computational strain of LOOCV has made it less popular
for large data sets, and as a result, its effectiveness in estimating
generalization error has not been thoroughly studied (20).
Monte Carlo Cross Validation is a third method of cross validation. It
introduces randomness by randomly splitting the cohort into a training set and
a test set. This process is repeated many times (e.g., 20, 50, or 1000 times).

26
It often employs similar splits to v-fold Cross Validation. For example, with
each iteration 90% of the observations may be in the training set and 10% in the
test set. As the number of iterations increases, this form of cross validation
becomes increasingly computationally expensive.
We chose to use (LOOCV) to estimate prediction error of our logistic
regression models. Despite its computational burden, LOOCV was chosen in
part because we had sufficient computing power to perform it. However, as
noted by Molinaro (20), it has a high variance when compared to less extreme
forms of v-fold cross validation. Compared to n-fold or Monte Carlo cross
validation, this may have created artificially large 95% confidence intervals,
decreasing the likelihood that we would achieve statistical significance with
our prognostic models when comparing them to the clinical gold standards of
TNM and NPI.

Model	
  Creation	
  with	
  Combination	
  Magic	
  
All computations were performed using The R Project for Statistical
Computing (RPS), an open-source language and environment. In pre-study
trials, the code for creating models was written in R alongside the R code for
analyzing the logistic regression model and computing the misclassification.
The limitation of this approach was several-fold. First, while R is an
excellent language for statistical analysis, data manipulation, and graphing, it
lacks the advanced programming features found in more traditional
programming languages. Examples include the availability of classic data
structures and strong debugging support. As a result, it was difficult to create
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a generalized algorithm for selecting all possible combinations of r from n, and
such an algorithm would still not have the flexibility for custom model creation
of the form we desired. Second, by integrating model selection into a
monolithic analysis run, we would not have the opportunity to selectively rerun part of the analysis in case of failure. Third, a graphical environment for
manipulating parameters related to model selection would be significantly
more user-friendly and offer improved ability to visualize the results of model
construction in advance of our computing runs.
We realized that by extracting the process of model creation from
execution of the statistical runs, we could solve each of these issues. A more
conventional programming language would provide us with the libraries and GUI
environment to create a flexible, generalized tool for model generation. Given
our familiarity with Java, this is the language we chose. By generating our
models in advance of the analysis run, and writing them out to multiple input
files, the failure of any one file would allow the others to proceed, and the
failed file could be re-run independently.
We wrote a Java program (Combination Magic) to accomplish this task of
model generation. Combination Magic evolved to handle several additional
features, which we will describe in the next paragraphs.
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Figure	
  7:	
  Combination	
  Magic	
  
Most simply, Combination Magic takes a list of variables (of length n) and
a “comparison level” (r) parameter that specifies how many variables should be
in each combination. For example, asking for all trivariate runs (taking r=3
from n=84) yielded 95,284 combinations (i.e., models) for our data set. (This is
according to the formula for combinations of r objects from n choices, n!/[r! *
(n-r)! ) The program’s output is two-fold. The text box on the left contains all
the possible combinations of the input variables. In turn, this is the input to
the model generator, which creates one or more models for each combination.
These models are displayed in the textbox on the right.
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Fundamentally, there are two types of models in Combination Magic,
which we call “additive” (e.g., A + B + C) and “interactive” (e.g., A*B*C). Note
that interactive models, such as “A*B”, should be used when the variables A
and B influence each other, with the expectation that the product of these two
variables will meaningfully improve the predictive value of the model.
Various parameters control the way that Combination Magic generates
models from the combinations. First, an “Include Smaller Levels” checkbox
allows the user to include multiple levels in the output; for example,
trivariate, bivariate, and univariate. Second, the “Exclude Non-Interactions”
checkbox allows you to remove pure additive models from the output. Often
you will want to run all additive models, and do all interactive models in a
following run. Third, Interaction Level specifies the level at which interactions
are produced. Note that this interaction level must be within the range of the
Comparison Level (from 2 to Comparison Level if “Include Smaller Levels” is
checked, otherwise just Comparison Level) to have any effect. Fourth, the
Sub-Interactions checkbox turns on generation of sub-interactions, while the
adjacent Vars input designates the maximum number of terms in each subinteraction. For example, when processing a quadvariate model, Vars = 3
would yield sub-interaction terms that included both two variables and three
variables, whereas Vars = 2 would just include the two-variable subinteractions.
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Combination	
  Magic	
  Use	
  Cases	
  

Figure	
  8:	
  Combination	
  Magic	
  Use	
  Case	
  #1	
  
This is a simple example of model creation. There are five variables and
the comparison level is one. Since each variable is only compared to itself, this
yields five possible models. Note that we specified Z as the outcome variable.
We also specified that the variable X should be included in every formula.
Note that any variable included in this manner will not participate in
comparisons, although this variable can be of any arbitrary form (e.g., an
interaction such as X*Y or a logarithmic variable such as log X).
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Figure	
  9:	
  Combination	
  Magic	
  Use	
  Case	
  #2	
  
Now we have specified a comparison level of 3. This creates models of
the form “Z~A+B+C”. Since we have checked “Include Smaller Levels”, we also
have models of the form “Z~A+B” (i.e., a comparison level of 2). In total, 25
models are created.
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Figure	
  10:	
  Combination	
  Magic	
  Use	
  Case	
  #3	
  
Now, in addition to a comparison level of 3, we have specified an
interaction level of 3. This interaction level creates interactions of the form
“A*B*C”. Since we have selected the “Sub-Interactions” check box, models will
also be created with smaller interactions up to the level specified. In this
case, this means the inclusion of interactions of 2 (e.g., A*B). In total, 10
combinations and 50 models are created.
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Combinatorial	
  Explosion	
  and	
  Java	
  Heap	
  Restrictions	
  
We quickly realized that combinatorial explosion would not only slow
down completion of our runs on the clusters, but also impact our ability to
generate the models in Combination Magic due to heap and stack overflows. In
order to solve the stack overflow problem, the recursive combination algorithm
was rewritten to avoid calling itself. (It is only a pseudo-recursive function in
that each call to the function only necessitates one “recursive” call until the
base case is eventually reached, not two or more.)
The heap overflow problem was more problematic. Java has a heap size
limit on various operating systems. On Windows, it is 1.6 gigabytes. Even after
optimization and allocation of the maximum amount of memory, heap size
would be exceeded whenever the number of models reached the low millions.
To solve this, we added the ability to selectively generate ranges of output
(e.g., combinations 500,000 to 999,999, and so forth). We also added a small
calculator, available in the “Calculate Combinations” tab, to calculate the
number of combinations to expect from a set of parameters r and n. This
assisted in our planning of runs, allowing us to generate maximum model
output without causing a heap overflow.
Despite these optimizations and workarounds, we reached a limit beyond
which we could not search exhaustively. For our data, exhaustively searching
the 5-variable space would require examining 30,872,016 models (5 from 84).
Because LOOCV requires repeating the generation of each logistic regression
model 539 times, alternating leaving out each patient, exhaustively searching
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the 5-variable space would actually require more than 16 billion distinct and
expensive logistic regression calculations, and that’s without interactions, subinteractions, or custom terms. We did not have enough computer power to
accomplish this task. Thus, we needed a new strategy.
For runs beyond quadvariate, instead of selecting from all 100 variables
(recall that each PI3-Kinase biomarker has several subcellular compartmental
expression levels), we split the variables into two "families". One family
consisted of the best subcellular compartmentalizations of the PI3K
biomarkers. The second family consisted of the AQUA and pathologist-scored
ErbB family markers and ER/PR, along with the clinical variables pTumor,
pMet, and pNode. We will refer to these as the PI3K and ErbB families,
respectively. 5- and 6-variable runs were performed on each family.
Next, we merged the results from each family into an aggregate run that
included the best models from each family. Combination Magic was extended
with new functionality to enable the merge. We will use the example of
creating a six-variable "merged" run from the best thirty models of the two 5variable runs of each family. The merge consisted of selecting six variables
from the pool of variables created by all pair-wise combinations of the top
models from one run with the top models of the second run. Variables were
extracted from each pair and then combined into one pool, with redundant
variables, when they existed, thrown out. If each 5-variable model lacks
redundant variables, this leaves a pool of ten variables, and selecting
combinations of six yields 210 combinations.
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There are 900 pair-wise combinations of 30 with 30, leading to 900 total
pools. Thus, the total number of models is potentially 900*210 = 189,000. In
practice, many duplicate models existed and were eliminated, but the
elimination of duplicate models was offset by the expansion of sub-interaction
terms. Thus, the pool actually involved twelve or more variables. In our case,
merging the top thirty models from the PI3K and ErbB families yielded 284,301
unique additive models without sub-interactions or interactions.
After completing a run with additive models only, we went one step
farther by also performing logarithmic expansion (each variable’s logarithmic
term was also added to the pool), treating sub-interaction terms as a variable
in their own right, and creating models with interactions and sub-interactions.
Due to combinatorial explosion, this required a reduction in the number of
models merged. We took the top ten models from the PI3K and ErbB families
and merged them together. This yielded 880,000 models with interactions and
sub-interactions, not including the additive models that had already been
processed.

Summary	
  
In summary, our attempts to find improved prognostic models in invasive
breast cancer when compared to the clinical gold standards of TNM staging and
the Nottingham Prognostic Index were not statistically significant. The
inability to achieve statistical significance was likely multifactorial. Broadly,
our focus on biological markers in the PI3 Kinase pathway only may have been
insufficient. There are many biological pathways important in human breast
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cancer, and their interactions are complex and not fully understood. Subgroup
analysis of HER2 positive patients may have increased the significance of our
results as the importance of the PI3 Kinase pathway is amplified in this group.
Refinement of our statistical methodology may have further increased
significance. Imputing missing data points may have lead to more accurate
models and narrower confidence intervals. Use of n-fold or Monte Carlo cross
validation methods may have also led to narrower confidence intervals.
Removing patients older than 80 from our cohort may have reduced the
influence of confounding comorbidities. Most significantly, we continue to
believe in the potential of biomarker analysis to improve upon existing
prognostic models in breast cancer and believe that this is an area deserving of
continued attention and research efforts.
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R	
  Statistical	
  Code	
  
doInit <- function() {
logistic = function(form, dat.sam, samx=samx, res.name, n.fold) {
options(warn = -1)
cv = unique(samx)[order(unique(samx))]
n.fold<-length(cv)
ret = list()
error = numeric(n.fold)
failures = 0
outcomes = 0
for( j in cv ) {
model.input = data.frame(dat.sam[which(samx!=j),])
names(model.input) = c(names(dat.sam))
#note: line below returns to original data to get the input row
outcome.input = data.frame(datx[j,])
outcome = NA #in case of failure
fxoutput = tryCatch({
model = glm(form, family=binomial, model.input)
outcome = predict( model, outcome.input, type="response")
}, error = function(ex) {
failed = "yes"
} )
if(!(is.numeric(fxoutput)) && !(is.na(fxoutput))) {
failures = failures + 1
} else if(!(is.na(fxoutput))) {
outcomes = outcomes + 1
}
error[j] = as.numeric((outcome > 0.5) != outcome.input$tenyrcens)
}
ret[[1]] = sum(error[cv], na.rm=T)/sum(!is.na(error[cv]))
ret[[2]] = outcomes
ret[[3]] = failures
return ( ret )
}
assign("logistic", logistic, envir=globalenv())
#read in data from data file
datx = data.frame(read.table("../YTMA49cleanNPI.txt", sep="\t",
header=T))
datx$tenyrcens = 1-datx$tenyrcens
#specify variables as factors here
datx$TumorType = factor(ifelse(datx$TumorType=="IDCNOS",0,ifelse(datx$TumorType=="IDClobft",1,ifelse(datx$TumorType=="IDCLowRisk",2,ifelse(datx$TumorType=="ILC",3,NA)))))
datx$HistoGrade =
factor(ifelse(datx$HistoGrade==1,"Low",ifelse(datx$HistoGrade==2,"Mediu
m",ifelse(datx$HistoGrade==3,"High",NA))))
datx$NuGrade = factor(datx$NuGrade)
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datx$Laterality = factor(ifelse(datx$Laterality ==
"L","L",ifelse(datx$Laterality=="R","R",ifelse(datx$Laterality=="B","Z"
,NA))))
datx$pTumor = factor(datx$pTumor)
datx$pMet = factor(datx$pMet)
datx$pNode = factor(datx$pNode)
datx$PathER = factor(datx$PathER)
datx$PathPR = factor(datx$PathPR)
datx$PathHER2 = factor(datx$PathHER2)
datx$NPI = factor(datx$NPI)
assign("datx", datx, envir=globalenv())
}
doBootstrap <- function(iter, offset) {
res.name <- "tenyrcens"
set.seed(as.integer(iter)) #sets seed for random number generator
#read in formulas from text file
formulas =
data.frame(read.table(paste("formulas",iter,".txt",sep="")))
#only takes one formula per input file
form = as.formula(as.character(formulas[1,1]))
n.confidence = 1000
misclassifications = numeric(1:n.confidence)
successes = numeric(1:n.confidence)
failures = numeric(1:n.confidence)
for( i in 1:n.confidence ) {
#build an array of the row values to sample
samx<-sample(c(1:nrow(datx)),nrow(datx),replace=TRUE)
#the data transformed by sampling
dat.sam <- datx[samx,]
#rerun the sampling algorithm if all rows are 0 or 1
while( sum(dat.sam[,res.name]) == nrow(dat.sam) |
sum(dat.sam[,res.name]) == 0 ) {
samx = sample(c(1:nrow(datx)), nrow(datx), replace=T)
dat.sam = datx[samx,]
}
ret = logistic(form, dat.sam, samx=samx, res.name=res.name,
n.fold=nrow(dat.sam))
misclassifications[i] = ret[[1]]
successes[i] = ret[[2]]
failures[i] = ret[[3]]
}
quants = quantile(misclassifications,c(0.025,0.975),na.rm=TRUE)
results.names =
list(c(as.character(formulas[1,1])),c("mean","median",".025",".975","su
ccesses","failures"))
results = matrix(nrow=1, ncol=6, dimnames=results.names)
results[1,] =
rbind(mean(misclassifications),median(misclassifications),quants[1],qua
nts[2],mean(successes),mean(failures))
results = round(results,3)
#write the results out to a numbered text file
write.table(results,file=paste("results",iter,".txt",sep=""))
}
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#for running the bootstrap
doInit()
doBootstrap(commandArgs()[5], commandArgs()[6])
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Tables	
  
Table	
  One:	
  AQUA-‐Measured	
  Variables	
  (Hormonal	
  Receptors	
  and	
  PI3	
  
Kinase	
  pathway)	
  
Variable
ER
EGFR

Explanation
Estrogen Receptor
Endothelial Growth
Factor Receptor

Variable
PR
HER2

HER3

Human Epidermal
Growth Factor Receptor
3
Extracellular signalRelated Kinases
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway

HER4

ERK
PI3Kp85
eIF4E
BCL2
AKT2
CMYC
FOX01
NFkB
PI3Kp110

PTEN
FOX03
p27kip1
AKT1
AKT3
CyclinD1
MTOR
p70S6K

Explanation
Progesterone Receptor
Human Epidermal
Growth Factor Receptor
2
Human Epidermal
Growth Factor Receptor
4
Phosphatase and Tensin
Homolog
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway
PI3 Kinase Pathway

Table	
  Two:	
  Clinical	
  Variables	
  
Variable
DiagAge
pTumor
HistoGrade
Laterality

Explanation
Age at Diagnosis
Tumor Size (TMN)
Histologic Grade
Light or Right

Variable
pMet
pNode
NuGrade
PathER

PathPR

Progesterone Receptor
(pathologist-scored)
Histologic Type

PathHER2

TumorType

Explanation
Metastasis (TMN)
Nodal status (TMN)
Nuclear Grade
Estrogen Receptor
(pathologist-scored)
HER2 Receptor
(pathologist-scored)

Complete	
  Univariate	
  Results	
  	
  
Univariate

Mis.Est.

AUC

n

Mean

0.025

0.975

NPI

0.326

0.644

473

0.326

0.292

0.359

~pNodal Stage

0.353

0.597

539

0.372

0.322

0.493
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TNM

0.367

0.609

~Metastasis
Stage

0.368

0.537

~Fox01_NU

0.369

~AKT1_TM

0.367

0.313

0.447

536

0.367

0.334

0.398

0.524

434

0.375

0.336

0.415

0.373

0.5

415

0.374

0.335

0.412

~PI3Kp110_TM

0.377

0.539

403

0.386

0.343

0.431

~mTOR_TM

0.382

0.5

429

0.383

0.346

0.419

~NFkB_TM

0.383

0.5

439

0.389

0.35

0.433

~HER2_MB

0.385

0.524

535

0.391

0.357

0.425

~PR_NU

0.385

0.5

473

0.385

0.352

0.421

~PTEN_TM

0.386

0.5

446

0.387

0.353

0.434

~p70S6K_NU

0.387

0.506

439

0.389

0.353

0.428

~CyclinD1_TM

0.388

0.5

456

0.389

0.356

0.424

~Nuclear Grade

0.39

0.569

502

0.400

0.358

0.538

~cmyc_TM

0.39

0.506

323

0.393

0.346

0.443

~Tumor Stage

0.392

0.566

502

0.373

0.332

0.506

~p70S6K_TM
(repeat)

0.392

0.506

439

0.388

0.351

0.423

~AKT2_TM

0.392

0.5

449

0.395

0.359

0.433

~eIF4E_NN

0.394

0.505

480

0.402

0.364

0.442

~BCL2_TM

0.394

0.5

462

0.396

0.359

0.449

~Age at
Diagnosis

0.395

0.5

539

0.399

0.366

0.441

~PI3Kp85_NU

0.397

0.498

466

0.399

0.365

0.436

~Laterality

0.398

0.5

530

0.407

0.367

0.47

~p27kip1_NU

0.398

0.5

427

0.402

0.363

0.439

44

~ER_NU

0.4

0.5

515

0.423

0.369

0.444

~AKT3_NU

0.401

0.5

362

0.403

0.361

0.446

~FOXO3A_MB

0.401

0.498

401

0.401

0.363

0.442

~PI3Kp85_NN
(repeat)

0.401

0.495

466

0.400

0.365

0.435

~AKT3_MB
(repeat)

0.403

0.508

362

0.404

0.363

0.449

~p27kip1_MB

0.403

0.5

427

0.404

0.365

0.447

~HER3_NN

0.404

0.511

488

0.402

0.365

0.439

~EGFR_MB

0.405

0.506

514

0.395

0.359

0.432

~PathER

0.407

0.5

509

0.424

0.372

0.642

~HER4_NN

0.409

0.5

472

0.409

0.373

0.446

~PathPR

0.409

0.5

494

0.433

0.377

0.664

~AKT3_NN
(repeat)

0.412

0.497

362

0.403

0.362

0.444

~ERK_TM

0.413

0.5

404

0.417

0.377

0.466

~TumorType

0.423

0.515

539

0.406

0.365

0.462

~Histologic
Grade

0.460

0.510

265

0.500

0.414

0.766

~PathHER2

0.471

0.5

499

0.423

0.379

0.492

Selected	
  Multivariate	
  Results	
  
5-variate

Mis.
Est.

AUC

n

Mean

0.025

0.975

Fox01_NU + AKT1_NU +
mTOR_MB + p70S6K_NU
+ AVG_BCL2_TM +
Fox01_NU*AKT1_NU*mT
OR_MB

0.295

0.587

285

0.33

0.274

0.393

Fox01_NU + AKT1_NU +
mTOR_MB +
AVG_BCL2_TM +

0.302

0.574

285

0.33

0.277

0.391

45

p70S6K_NN +
Fox01_NU*mTOR_MB*p7
0S6K_NN
Fox01_NU +
PI3Kp110_TM +
mTOR_MB + p70S6K_NN
+ FOXO3A_NN +
Fox01_NU*PI3Kp110_TM
*mTOR_MB*FOXO3A_N
N

0.301

0.666

279

0.337

0.28

0.401

ER_NU + HER3_NN +
HER4_NN + pMet +
pTumor +
HER3_NN*pTumor

0.310

0.663

393

0.345

0.294

0.399

ER_NU + HER3_NN +
HER4_TM + pMet +
pTumor +
HER3_NN*pTumor

0.315

0.659

394

0.348

0.295

0.406

HER3_NN +
log(HER4_NU/HER4_NN)
+ PathPR + PathHER2 +
pTumor +
log(HER4_NU/HER4_NN)
*PathPR*PathHER2

0.316

0.702

380

0.355

0.301

0.411

log(HER4_NU/HER4_NN)
+ PathER + PathPR +
pMet + pNode +
PathER*PathPR*pNode

0.317

0.699

441

0.373

0.314

0.443

Mis.
Est.

AUC

n

Mean

0.025

0.975

Fox01_NU + AKT1_NU
+ mTOR_MB +
AKT2_NN +
AVG_BCL2_TM +
p70S6K_NN +
Fox01_NU*AKT1_NU*m
TOR_MB

0.295

0.593

285

0.331

0.273

0.401

Fox01_NU + AKT1_NU
+ mTOR_MB +
cmyc_NU +
AVG_BCL2_TM +
p70S6K_NN +
AKT1_NU*p70S6K_NN

0.297

0.627

195

0.333

0.266

0.403

Fox01_NU + AKT1_NN

0.295

0.590

285

0.334

0.277

0.403

6-variate

46

+ mTOR_MB +
p70S6K_NU +
AKT2_NN +
AVG_BCL2_TM +
Fox01_NU*mTOR_MB*p
70S6K_NU
ER_NU + HER3_NN +
HER4_NN +
log(HER4_NU/HER4_N
N) + pMet + pTumor +
HER3_NN*pTumor

0.313

0.663

393

0.348

0.298

0.41

ER_NU + HER2_MB +
HER3_NN + HER4_MB
+ HER4_NN + pTumor +
HER3_NN*pTumor

0.311

0.658

395

0.348

0.3

0.402

47

6-variate “Merge”

Mis.
Est.

AUC

n

Mean

0.025

0.975

AVG_BCL2_TM +
Fox01_NU*AKT1_NU*m
TOR_MB + HER4_MB +
HER4_NN +
p70S6K_NU + pTumor +
HER4_NN*pTumor

0.247

0.728

243

0.303

0.240

0.370

AKT1_NU +
AVG_BCL2_TM +
Fox01_NU*mTOR_MB*p
70S6K_NN + HER4_MB
+ HER4_NN + pTumor +
HER4_MB*pTumor

0.259

0.704

243

0.304

0.243

0.379

AKT1_NU +
AVG_BCL2_TM +
Fox01_NU*mTOR_MB*p
70S6K_NN + HER4_MB
+ HER4_NN + pTumor +
HER4_NN*pTumor

0.259

0.713

243

0.304

0.238

0.371

AVG_BCL2_TM +
Fox01_NU*AKT1_NU*m
TOR_MB + HER4_MB +
HER4_NN +
p70S6K_NN + pTumor +
HER4_NN*pTumor

0.247

0.728

243

0.305

0.241

0.374

AVG_BCL2_TM +
Fox01_NU*AKT1_NU*m
TOR_MB + HER4_MB +
HER4_NN +
p70S6K_NN + pTumor +
HER4_MB*pTumor

0.259

0.731

243

0.305

0.240

0.378

Fox01_NU +
Fox01_NU*AKT1_NU*m
TOR_MB +
HER3_NN*pTumor +
HER4_NN +
p70S6K_NU + pMet +
Fox01_NU*HER3_NN*p
Tumor

0.258

0.690

260

0.325

0.263

0.394

